Physician profile
Mark Farber
NPI 1033552187
$5,550.79
in general payments reported to CMS, 2019-2025
27 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $40.39 · 2021: $218 · 2022: $2,545 · 2023: $493 · 2024: $948 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $2,016.00 | 2022 | |
| Abbvie INC. | $1,203.12 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $384.90 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $375.44 | 2022-2025 | |
| Lilly USA, LLC | $205.43 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.57 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $141.23 | 2024-2025 | Rexulti |
| Bausch Health US, LLC | $127.09 | 2020-2024 | Aplenzin, Wellbutrin |
| Angiodynamics, INC. | $112.50 | 2021 | |
| Amgen INC. | $107.85 | 2021-2025 | Repatha, Repatha, Otezla |
| Vifor Pharma, INC. | $102.44 | 2019 | |
| Pfizer INC. | $95.38 | 2020-2025 | |
| Novo Nordisk INC | $72.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Paratek Pharmaceuticals, INC. | $70.04 | 2022-2024 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $65.34 | 2021-2024 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $53.35 | 2023-2024 | Inpefa |
| Collegium Pharmaceutical, INC. | $32.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.05 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.84 | 2024 | Onpattro |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.70 | 2022 | |
| Acerus Pharmaceuticals Corporation | $20.86 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.13 | 2025 | |
| Mayne Pharma Commercial LLC | $17.89 | 2023 | |
| Gilead Sciences, INC. | $16.37 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.51 | 2024 | Gvoke Hypopen |
| Shield Therapeutics INC | $13.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Farber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.